Literature DB >> 20483474

Testing the antagonistic pleiotropy model of schizophrenia susceptibility by analysis of DAOA, PPP1R1B, and APOL1 genes.

Noa Carrera1, Manuel Arrojo, Eduardo Paz, Ramón Ramos-Ríos, Santiago Agra, Mario Páramo, Julio Brenlla, Javier Costas.   

Abstract

Schizophrenia is a common disease associated with reduced fertility. Therefore, the existence of common susceptibility alleles not removed by natural selection may be considered an evolutionary paradox. The antagonistic pleiotropy model, proposed to explain this paradox, states that an allele may be common because of its overall selective advantage, in spite of deleterious effects on specific traits. Recent work on DAOA, PPP1R1B, and APOL1 suggests that these genes present common alleles associated to increase risk of schizophrenia but conferring an overall selective advantage, related to better cognitive performance (DAOA and PPP1R1B) or protection against pathogens (APOL1). To test if these genes fit the antagonistic pleiotropy model, we searched for recent natural selection at these loci applying the long-range haplotype test on data from the HapMap Project; and performed case-control association analysis in a well-powered sample, including 301 schizophrenic patients and 604 controls from Spain. For DAOA and PPP1R1B, we genotyped the Single-nucleotide polymorphisms (SNPs) needed to replicate previous associations, while for APOL1, we genotyped 15 tagSNPs, and seven putative functional SNPs. We did not detect evidence of recent natural selection. Furthermore, we did not find significant associations. Thus, these genes do not fit the antagonistic pleiotropy model.
Copyright © 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483474     DOI: 10.1016/j.psychres.2009.05.014

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

1.  Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression.

Authors:  Y Kunii; T M Hyde; T Ye; C Li; B Kolachana; D Dickinson; D R Weinberger; J E Kleinman; B K Lipska
Journal:  Mol Psychiatry       Date:  2013-01-08       Impact factor: 15.992

Review 2.  APOL1 Kidney Disease Risk Variants: An Evolving Landscape.

Authors:  Patrick D Dummer; Sophie Limou; Avi Z Rosenberg; Jurgen Heymann; George Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Semin Nephrol       Date:  2015-05       Impact factor: 5.299

Review 3.  Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.

Authors:  Chien-An A Hu; Edward I Klopfer; Patricio E Ray
Journal:  FEBS Lett       Date:  2012-03-08       Impact factor: 4.124

4.  The analysis of APOL1 genetic variation and haplotype diversity provided by 1000 Genomes project.

Authors:  Ting Peng; Li Wang; Guisen Li
Journal:  BMC Nephrol       Date:  2017-08-11       Impact factor: 2.388

5.  The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers.

Authors:  Valentina Citro; Chiara Cimmaruta; Maria Monticelli; Guglielmo Riccio; Bruno Hay Mele; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.